Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17585394 | 0.94 | TSHR (0.65) | TSHRMAPK1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29458475 | 0.88 | TSHR (0.81) | TSHRMAPK1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13831345 | 0.78 | CYP1A2 (0.65) | TSHRALDH1A1SMN1; SMN2KDM4ETDP1 | |
| SCHEMBL13832027 | 0.78 | NPSR1 (0.70) | TSHRALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL18559277 | 0.78 | TSHR (1.00) | TSHRMAPK1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4209334 | 0.77 | MAPT (0.71) | TSHRMAPK1ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL13831882 | 0.76 | KMT2A (0.71) | TSHRMAPK1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL18559288 | 0.76 | ALDH1A1 (0.67) | TSHRMAPK1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL13831340 | 0.76 | NPC1 (0.69) | TSHRMAPK1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4210817 | 0.75 | ALDH1A1 (0.72) | TSHRMAPK1ALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241578-A1 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | UNIV DREXEL (US) | 2019-08-08 | — | — | US | claimed |
| US-20170190709-A1 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | UNIV DREXEL (US) | 2017-07-06 | — | — | US | claimed |
| US-20160074408-A1 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2016-03-17 | — | — | US | claimed |
| WO-2014172453-A2 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | PHILADELPHIA HEALTH AND EDUCATION CORPORATION D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE (US) | 2014-10-23 | — | — | WO | claimed |
| US-20190241578-A1 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | UNIV DREXEL (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190241578-A1 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | UNIV DREXEL (US) | 2019-08-08 | — | — | US | disclosed |
| US-10287290-B2 | Compositions useful in treating brain-related diseases or disorders and methods using same | DREXEL UNIVERSITY (US) | 2019-05-14 | — | — | US | disclosed |
| US-10287290-B2 | Compositions useful in treating brain-related diseases or disorders and methods using same | DREXEL UNIVERSITY (US) | 2019-05-14 | — | — | US | disclosed |
| US-20170190709-A1 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | UNIV DREXEL (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190709-A1 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | UNIV DREXEL (US) | 2017-07-06 | — | — | US | disclosed |
| US-9616065-B2 | Compositions useful in treating brain-related diseases or disorders and methods using same | DREXEL UNIVERSITY (US) | 2017-04-11 | — | — | US | disclosed |
| US-9616065-B2 | Compositions useful in treating brain-related diseases or disorders and methods using same | DREXEL UNIVERSITY (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160074408-A1 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2016-03-17 | — | — | US | disclosed |
| WO-2014172453-A2 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | PHILADELPHIA HEALTH AND EDUCATION CORPORATION D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE (US) | 2014-10-23 | — | — | WO | disclosed |
| WO-2014172453-A2 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | PHILADELPHIA HEALTH AND EDUCATION CORPORATION D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE (US) | 2014-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241578-A1 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | SLC18A2, SLC6A2, SLC1A2 | TSHR 2198/4885MAPK1 3784/4885L3MBTL1 4464/4885 |
| US-20170190709-A1 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | SLC18A2, SLC6A2, SLC1A2 | TSHR 2198/4885MAPK1 3784/4885L3MBTL1 4464/4885 |
| US-10287290-B2 | Compositions useful in treating brain-related diseases or disorders and methods using same | SLC18A2, SLC6A2, SLC1A2 | TSHR 2292/4885MAPK1 3752/4885L3MBTL1 4549/4885 |
| US-20160074408-A1 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | SLC18A2, SLC18A3, SLC1A2 | TSHR 2338/4885MAPK1 3662/4885L3MBTL1 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.